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“(…) if I will die it will be in Bombo, if I 
live it will be in Bombo. ‘till now I never 
went to another hospital” (Interviewee 3, 
Section 220). 
1. Introduction 
With an estimated 33 million people infected with the Human Immunodeficiency Virus 
(HIV) worldwide and 2.6 million newly occured infections in the year of 2009 (Joint United 
Nations Programme on HIV/AIDS (UNAIDS) 2010), the infection with HIV and its 
Acquired Immunodeficiency Syndrome (AIDS) has developed to a pandemic and the 
greatest health crisis around the globe (see Figure 1). With a total of 22 million people 
infected in sub-Saharan Africa alone and 1.3 million AIDS-related deaths registered in 
2009, HIV and AIDS has a drastic impact not only onto the lives of individuals and their 









Although no cure for HIV could be invented so far, life-long highly active antiretroviral 
treatment (HAART) has been successfully developed for people infected. However, costs 
                                                 
1 The data collection for this thesis was conducted during the year of 2008. Within this section I therefore refer 
to data reflecting to the overall situation at this very time span and allowing to embed the data collected into 
the time elapsed. In 2014 the total number of people living with HIV (all ages) worldwide had increased to 
36.9 million. The HIV-prevalence rate in 2014 among adults (age 15-49) was estimated to be 0.8% (UNAIDS 
2015).  
Figure 1: Global HIV-prevalence rate in 2009 (UNAIDS 2010, p. 23)  
1. Introduction 
 2 
for the medication remained high, with only 2% of people in low- and middle-income 
countries receiving antiretroviral therapy (ART) by 2001 (WHO 2002). 
Access remained limited in particular due to the Trade-Related Aspects of Intellectual 
Property Rights (TRIPS) treaty, passed and adopted by countries in 1994, later forming the 
World Trade Organization (WTO) and ensuring patent protection and copyrights for 
pharmaceutical goods for a total of 20 years following development (Mutume 2001).2  
Meanwhile human rights activists raised their voice, claiming access to HIV treatment a 
human right. Among them was the Treatment Action Campaign (TAC), founded in 1998 
and developing to the leading voice in Africa, claiming access to HIV treatment for all 
South Africans, prioritizing patients’ rights over property rights (Hardon and Dilger 2011; 
Treatment Action Campaign (TAC) 2015). It was when Médecins Sans Frontières (MSF) 
approached TAC in 1999, in order to launch a Prevention of Mother to Child Transmission 
(PMTCT) pilot project, when events started to overturn (Neumann 2011). Cipla Limited, a 
generic drug company from India, offered generic drugs to MSF’s pilot projects for 10% of 
the total price of patented drugs in early 2000 (Hardon und Dilger 2011). And only a year 
later, in April 2001, a total of 39 countries dropped a lawsuit against the South African 
government for allowing to provide generic drugs to patients, turning to a milestone in the 
history for universal access to treatment (Mutume 2001).  
With the production of generic drugs in 2001 prices dropped from 10,400 US$ per year and 
person in May 2000 to 295 US$ per year in October 2001 (MSF 2001), making 
antiretrovirals (ARVs) available to a wider HIV-seropositive public, in particular with a 
scale up of treatment availability in resource-poor settings. A further decrease in price could 
be observed in low-income countries, with a median price of 64 US$ per year/person for the 
most common prescribed treatment regimen combination for adults (WHO 2010). 
With the drastic spread of HIV and the affordability of HAART the World Health 
Organization declared the 3 by 5 initiative in 2003, launching treatment to 3 million HIV-
seropositive people by the end of 2005. A milestone within the target of universal access to 
treatment was set, leading to the following optimistic assumptions by the World Health 
Organization (WHO): 
“Universal access to antiretroviral therapy for everyone who requires it according to 
medical criteria opens up ways to accelerate prevention in communities in which more 
people will know their HIV status – and, critically, will want to know their status. As 
HIV/AIDS becomes a disease that can be both prevented and treated, attitudes will 
                                                 
2 Nevertheless, it was agreed on a transitional period for the implementatin of TRIPS, allowing the majority of 
“developing” countries to adopt the treaty the latest by the year of 2000 and “least developed” countries by the 
year of 2006 (Mutume 2001). 
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change, and denial, stigma and discrimination will rapidly be reduced. Rolling out 
effective HIV/AIDS treatment is the single activity that can most effectively energize 
and accelerate the uptake and impact of prevention. Under 3 by 5, this will occur as 
part of a comprehensive strategy linking treatment, prevention, care and full social 
support for people affected by HIV/AIDS. Such support is critical – both to ensure 
adherence to antiretroviral therapy and to reinforce prevention” (WHO 2003a, p. 6; 
emphasis Leah-Franziska Bohle (LFB)).   
 
Great hopes were raised by advocaters for universal access to treatment in regard to the 
social impact of treatment availability leading to a decrease of discrimination in connection 
with the infection and disease. However, chances outshined a discussion about emerging 
challenges caused by a life-long treatment with pills and its concomitant factors onto the 
people infected.  
 
Few years later and with a success in treatment coverage of 5.2 million people – of an 
estimated total of 15 million infected people in need in low- and middle-income countries3 
–, UNAIDS commented their progress within the UNAIDS Report on the Global AIDS 
Epidemic 2010, though euphoria gave way to cautious reticence:  
“The question remains how quickly the response can chart a new course towards 
UNAIDS’ vision of zero discrimination, zero new HIV infections, and zero AIDS-
related deaths through universal access to effective HIV prevention, treatment, care 
and support” (UNAIDS 2010, p. 7).4  
 
By the end of 2008 and since the scaling up of universal access to treatment, an estimated 
total of 4 million people received HIV treatment in low-income countries. Among these, a 
total of 2.4 million people received treatment in southern and eastern Africa alone, with a 
30-fold increase in people treated for HIV in sub-Saharan Africa since the end of 2003 
(WHO 2008). 
1.1 The Research Project 
In February 2006 I was fortunate to conduct a clinical elective at the Groote Schuur 
Hospital in Cape Town, South Africa. Witin this elective I could assist a doctor with his 
                                                 
3 The WHO, the US President’s Emergency Plan for AIDS Relief (PEPFAR), the Global Fund to Fight AIDS, 
Tuberculosis and Malaria and further partners were joined by UNAIDS in July 2013 to launch the Treatment 
2015 initiative. The initiative aims for universal access to treatment and the coverage of 15 million people 
worldwide treated with ARVs until 2015 (UNAIDS 2013). A total of an estimated 9.7 million people in low- 
and middle-income countries received ART by December 2013. With an estimated 28.6 million people eligible 
for treatment in 2013, this represents only 34% receiving needed treatment, showing that increase of treatment 
– in particular in low- and middle-income countries – is more than ever needed (UNAIDS 2013).  
4 Until now, the elimination of “HIV-related stigma, discrimination, punitive laws and practices” (UNAIDS 
2013, p. 1/p. 84-97) remains one of the ten most primary concerns as indicated in the recent UNAIDS Report 




HIV-consultations at the Nolungile Hospital in the township of Khayelitsha – the hospital 
where MSF first launched its ART pilot project in the year of 2000.  
While assisting during the consultations I came across the manifold challenges caused by 
access to antiretroviral treatment. In particular, HIV-seropositive women reported of the 
difficulties of avoiding involuntary disclosure and hiding the monthly ration of medication 
in their township houses, which were often shared by many people and with very limited 
privacy. These profound experiences with HIV-seropositive women in South Africa led to 
the idea of focusing on the impact of ART onto the lives of women infected with HIV and 
enrolled on antiretroviral treatment in Tanzania.  
 
The clinical-based qualitative research project was conducted in the United Republic of 
Tanzania5 in the year of 2008. At the time, Tanzania had an estimated HIV prevalence rate 
among adults of 6.2% (UNAIDS 2008), with a total of approximately 1.4 million people 
infected (PEPFAR 2012). Within the research area of Tanga Region, prevalence rate 
between 4.5% and 6.9% fairly equaled the national rate (UNAIDS 2008) with significantly 
more women affected (UNAIDS 2010).  
With the implementation of access to free antiretroviral treatment in 2004, the number of 
people enrolled on treatment increased countrywide from 2,000 people in the first year of 
free treatment availability (Tanzanian Commission for AIDS (TACAIDS) 2009) to nearly 
200,000 by 2009 (UNAIDS 2010).6 At the time of research conduction a total of 6,300 
HIV-seropositive patients – with the overall majority being female – were officially 
registered at the Care and Treatment Center (CTC) at the public Bombo Regional Hospital 
in Tanga City, serving as research location.  
 
With the availability of free ART and an expected change in disease perception from a 
deadly to a chronic and treatable disease, a major reduction in discriminating attitudes 
towards HIV was widely anticipated as outlined above – hence, possibly resulting in a 
change in disclosure rates and patterns. This multi-methodological research study focused 
on the process of verbal self-disclosure in an era of treatment availability, giving voice to 
                                                 
5 To ensure readability solely the term Tanzania is used when referring to the United Republic of Tanzania. 
6 Available antiretroviral medications were the combination of either two nucleoside reverse transcriptase 
inhibitors (NRTIs) and one non-nucleoside reverse transcriptase inhibitor (NNRTI) or two nucleoside reverse 
transcriptase inhibitors (NRTIs) and one protease inhibitor. First-line antiretroviral medications in use were 
Triomune 30 or Combivir combined with either Nevirapine or Efavirenz. Second-line medication offered were 
Didanosine in combination with Abacavir or Lopinavir/Ritonavir (Kaletra). No additional ARVs were 




the people infected and shedding light onto the social impact of ART on their lives in regard 
to chances and challenges caused by treatment availability.  
In particular, this study focused on reasons for disclosure and non-disclosure, the choice of 
the first person and the following significant others to inform or intentionally not inform 
and reactions to disclosure. Furthermore we have asked our interviewees about their 
(voluntary) counseling and testing (VCT) experiences, reasons for testing, satisfaction of 
staff performance at CTC, their suspected mode of transmission, condom use, experiences 
with traditional healers and ART. Futhermore we collected detailed socio-demographic and 
medical data.  
During research conduction and with final data analysis the following core topics emerged: 
1) reasons for disclosure and non-disclosure and the choice of significant others (not) to 
inform, 2) reactions to disclosure experienced, 3) the perception of HIV and AIDS, as well 
as 4) adherence to ART among HIV-seropositive women enrolled on treatment. With the 
first topic dealt with in the publication related to this thesis, we would like to focus on the 
latter (2-4) and briefly present further results concerning reactions to disclosure, the 
perception of HIV and AIDS and experiences made with ART reported by our interviewees 
in regard to the social impact of ART on the lives of infected.  
 
1.2 Publication of Results 
Due to a wealth of data collected, the data and findings were divided and used for several 
publications – specifically the Magisterarbeit (i.e. M.A. thesis) and the medical doctoral 
dissertation – as listed above.  
The M.A. thesis is titled „Stigmatization, discrimination and illness. Experiences among 
HIV-seropositive women in Tanga, Tanzania“ and was submitted at the Faculty of Social 
Sciences on 3 August 2011. It was published as a book at the Göttinger Universitätsverlag 
at the end of 2013 with the identical title.  
The medical dissertation submitted is publication based. The publication is titled „HIV-
serostatus disclosure in the context of free antiretroviral therapy and socio-economic 
dependency: experiences among women living with HIV in Tanzania“ and was published in 
the African Journal of AIDS Research“ on 12 November 2014.  
Although the publications are based on the same datasets, the topics and research 
question(s) investigated, the amount of data, the methodological and analytical approach as 
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well as the literature cited, differ greatly.7 The M.A. thesis focuses on stigmatization and 
discrimination as a social phenomenon, as well as illness (i.e. a subjective experience) 
versus disease (i.e. a biomedical terminology) in relation to HIV and is embedded in a 
medical-anthropological context. In contrast, the medical dissertation thesis focuses on 
disclosure of the HIV-seropositive status including related sub-topics. Here, (non-
)disclosure is approached from a Public Health angle and social, emotional and economic 
reasons for disclosure and non-disclosure are discussed.  
The M.A. thesis uses an ethnographic approach, presenting a selection of six interviews in 
depth. Here mainly qualitative data (through a biographical approach) and direct citations 
are used and supported by participant observation. Quantiative socio-demographic data of 
the overall sample is presented to justify the selection of the six intervieweews presented in 
detail. The medical dissertation thesis however, presents the quantitative data in detail and 
presents the full set of qualitative data mainly through quantification and few direct 
citations.  
Overall 149 different bibliographical sources were referred to in the M.A. thesis, with a 
specific focus on stigmatization and discrimination in relation to HIV, and in contrast to 57 
literature sources cited in the publication of the medical doctoral dissertation, with a specific 
emphasis on disclosure. Overall, a total of nine publications were identical in the M.A. 
thesis and medical doctoral dissertation. These sources however refer to country data and 
the methodology with two exceptions: one book published by Dilger in 2005 titled “Leben 
mit Aids“, as well as one article, focusing on stigmatization as well as the disclosure of the 
HIV-seropositive status and attitudes towards the treatment of HIV by Zou et al. (2009). 
1.3 A Literature Review of the Core Topics 
The anticipated change in disease perception with the implementation of ART has only been 
marginally explored. According to the Tanzania HIV/AIDS and Malaria Indicator Survey 
2007-08, which collected data from October 2007 to February 2008 and prior to our study 
commencement (March 2008), levels of discrimination among the Tanzanian communities 
remain high (TACAIDS et al. 2008). However, Roura et al. showed a unique development 
of the perception of HIV and AIDS as being a normal disease among HIV-seropositive 
patients from an HIV-department receiving ART (Roura et al. 2009).  
With an anticipated reconceptualization of HIV and AIDS coming along with ART 
availability, a change in reactions by significant others disclosed to could also be expected. 
                                                 
7 For a detailed overview on the methodological approach and data analysis related to the publications, please 
view Chapter 3. 
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Before the advent of HAART, reactions to HIV-serostatus disclosure among women have 
been researched in the United States of America (USA), Western Europe, sub-Saharan 
Africa and Asia (Keogh et al. 1994; Simoni et al. 1995; Gielen et al. 1997; Medley et al. 
2004; WHO 2003b), though only few in number and with a strong focus on reactions by the 
women’s partners only. Within the two literature reviews available, reactions resembled and 
ranged from positive outcomes, such as encouragement and kindness (Medley et al. 2004), 
to increased support and acceptance (WHO 2003b). Negative outcomes experienced were 
blame and stigma, abandonment, anger, separation and violence (Medley et al. 2004; WHO 
2003b). However, violence was rarely mentioned, with a higher degree in the USA and 
Western Europe (WHO 2003b). After the access to treatment availability outcomes of 
disclosure have again been marginally researched and with a regional focus on sub-Saharan 
Africa (Deribe et al. 2008; Gari et al. 2010).  
Within the United Republic of Tanzania very few authors have dealt with the actual 
outcome of disclosure before the availability of ART (Kilewo et al. 2001; Maman et al. 
2003; Dilger 2005), with Kilewo et al. and Maman et al. addressing reactions by the sexual 
partners of HIV-seropositive women only. Reactions by partners were mostly positive, with 
only few HIV-seropositive women experiencing blame, assault, violence or separation 
(Kilewo et al. 2001; Maman et al. 2003). However, one individual interviewed by Dilger 
(2005) reported of blame, denial of support and withdrawal of his family. Among the few 
studies on this topic conducted in Tanzania since the availability of antiretroviral treatment 
(Greeff et al. 2008; Lugalla et al. 2008; de Klerk 2012; Moyer 2012; Bohle 2013; Bohle et 
al. 2014) positive and negative outcomes were reported, ranging from accusation, denial, 
animosity, emotional and physical withdrawal, furiosity and blame, psychological abuse, 
separation and exclusion amongst others (Greeff et al. 2008; Lugalla et al. 2008; Moyer 
2012; Bohle 2013). However, studies differed greatly concerning location, research 
question, study sample and methodology.  
Within the studies conducted by Greeff et al. (2008) and Lugalla et al. (2008) in Tanzania, 
ART was no mandatory selection criteria, while both recruited patients from support 
groups. Here it can be expected that people visiting a support group, having disclosed to its 
members and deliberately confronting themselves with their infection, are also dealing more 
openly with their disease, hence leading to a bias in results.   
 
Prior to the implementation of universal access to treatment, influential opponents, such as 
Andrew Natsios, at the time administrator of the United States Agency for International 
Development (USAID), voiced great doubts with the ability of “Africans” to adhere to 
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complex treatment regiments in resource-poor settings (Donnelly 2001). Optimal adherence 
to HAART – ideally of 95% or higher – is of great importance (Paterson et al. 2002), not 
only to secure the stabilization of the health condition of the infected and to minimize the 
viral load and risk for infection of others, but to also avoid possible development of 
resistances in particular with regard to only first- and second-line treatment availability as 
the case in the majority of low-income countries until now. 
Adherence rates have been widely researched since the availability of HAART. The 
inability of adhering to antiretroviral therapy by people infected in low-income countries, as 
widely claimed by opponents of universal access, did not proof true. In the contrary, much 
greater adherence rates could be shown in resource-poor settings, compared to those of 
industrialized countries (Ivers et al. 2005; Mills et al. 2006a; Mills et al. 2006b; Attaran 
2007; Ware et al. 2009a), leading to the urgent questions of why do people have such higher 
adherence rates and how do people perceive and respond to ART?  
In the United Republic of Tanzania, numerous studies have been published, focusing on 
influencing factors on adherence rates since the availability of HAART. While several 
studies have dealt with obstacles to adherence (WHO 2006; Hardon et al. 2007; Ramadhani 
et al. 2007; Dlamini et al. 2009; Irunde et al. 2009; Makoae et al. 2009; Watt et al. 2010; 
Baltazary et al. 2011; Mattes 2011; Lyimo et al. 2012; Lyimo et al. 2014; Thielman et al. 
2014), few have presented results on reasons supporting adherence to ART (Watt et al. 
2009; Ware et al. 2009b; Watt et al. 2010; Lyimo et al. 2012). However, the social impact 
and perception towards antiretroviral treatment among HIV-seropositive people in Tanzania 
remain mostly unknown while qualitative in-depth studies are needed.  
 
The summary presented below provides a brief overview of the research conducted in 
Tanzania. First, and for a better understanding of the location, the research setting will be 
described. Second, and within the chapter of methodology, insight is given into the overall 
structure of the research study, including the study participants, the recruitment process, the 
protection of human participants and the methodological approach, as well as the data 
analysis in use.  
Following, selected data on the main topics of interest evolved during interviewing will be 
presented, focusing on reactions to disclosure, the reconceptualization of HIV among our 
interviewees, reasons and strategies of ART adherence and perception and impact of 
HAART on the lives of our interviewees. Finally I would like to discuss the results 
presented and comprise with a conclusion and a way forward.  
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2. Research Setting 
The Care and Treatment Center located at the Bombo Regional Hospital (BRH) in Tanga, 
Tanzania, was chosen as research location. The BRH is the main and leading University 
affiliated hospital in Tanga Region, providing biomedical treatment to a population of more 
than 242,000 people in Tanga District alone (National Bureau of Statistics and Ministry of 
Planning, Economy and Empowerment 2006). The CTC, inaugurated in June 2006 and 
supported by several international and national stakeholders,8 served the needs of 6,300 
registered HIV-seropositive patients in 2008, with the majority (69%) being female and more 
than half enrolled on antiretroviral treatment.9 Hence, the department was daily crowded with 
people, waiting for testing, medical check-ups, the commencement of ART, adherence 
classes or the prescription of further medication. At the time the department itself was 
incorporated into the hospital and included a Voluntary Counseling and Testing Center 
(VCTC), several offices for medical consultations, a laboratory, a pharmacy, as well as rooms 
for regular education sessions.  
                                                 
8 For further information please see Mattes (2011).  
9 According to an informal interview in October 2013 with staff from the CTC at BRH, over 10,000 patients 
were registered at the newly built HIV clinic located on the hospital compound. 
Figure 3: A young woman being tested for 
HIV at the VCTC at Bombo Regional Hospital 
(LFB, 2008)  
Figure 2: An HIV rapid test conducted by the 
nurse at the VCTC at Bombo Regional Hospital 
(LFB, 2008)  
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Prior to ART commencement patients had to attend three mandatory adherence classes, 
during which they received information on the disease, such as possible modes of 
transmission, as well as the medication, dosage taking, symptoms, side effects, and optimal 
nutrition.10 Adherence rates could only be indirectly measured, recording pill counts 
conducted by the pharmacists during refill of medication bottles, questioning and self-report 
of the patients in case of remaining pills and a CD4 count check approximately every 3-6 
months. However, plasma HIV-1 RNA levels could not be measured.  
The staff at the CTC included several Assistant Medical Officers (AMOs)11, specially trained 
nurses, pharmacists, data clerks and volunteers.  
 
The Tanga AIDS Working Group (TAWG), a non-governmental organization inaugurated as 
early as 1992, is also located at the hospital compound and widely known for its longtime 
care and support of people living with HIV and AIDS (PLWHA). It not only offers VCT and 
HIV-testing at multiple testing centers in Tanga City, but herbal medicine to HIV-
seropositive patients not yet enrolled on ART due to a high CD4 count, as well as Home 
Based Care (HBC). It also provides trainings for traditional healers and works in close 
collaboration with the BRH and traditional healers in the region (TAWG 2010; Personal 
interview with Dr. Firimina Mberesero, founder of TAWG, Tanga City, 08.08.2008).   
Besides its biomedical treatment options, Tanga District remains famous for the power of its 
traditional healers (mganga kwa kienyeji), their herbal medicine (dawa za mitishamba) and 
spiritual powers (kwa ramli)12, with people from all over the country coming to Tanga 




                                                 
10 For further information concerning adherence classes at the department please see Mattes (2011). 
11 Assistant Medical Officers (AMOs) have finished medical studies at university and have undergone special 
health care courses being in the position between a Clinical Officer and a Medical Officer, which can be 
compared to the tasks of a resident. They are able to provide curative and preventive services, and are eligible to 
conduct minor operations (Pemba 2008). 
12 In brackets are the expressions in Kiswahili, together with English, the offical languages in Tanzania.  
13 According to the National Bureau of Statistics (NBS) a total of 15% of the total Tanzanian population on the 
mainland visit traditional healers, among these about 5.5% of urban residency (2002). For further information on 
spirit possession at the Swahili coast please see Giles (1989) with results based on three years of fieldwork from 
1982-1984 for her PhD thesis. For further information on healing in Tanzania please see Langwick (2011), and 
for information particular on Tanga, please see the book written by Mackenrodt entitled Swahili Spirit 




3.1 Research Design, Ethical Clearance and Research Team 
For this clinic-based research study, a multi-methodological approach was chosen, including 
the conduction of participant observation at the CTC and during interviews with patients, 
questionnaires and semi-structured guideline interviews with HIV-seropositive women 
enrolled at the CTC. Further, semi-structured guideline interviews with hospital staff, the 
founder of the TAWG and the Regional AIDS Control Coordinator of Tanga Region were 
undertaken, as well as informal interviews during the research phase.  
The study received ethical clearance from the ethical committee of Göttingen University and 
the National Institute for Medical Research in Tanzania (NIMR), as well as research 
permission from the Commission of Science and Technology (COSTECH) in Tanzania.  
The research team consisted of two female Tanzanian interviewers with no prior employment 
at the hospital, fluent in English and Kiswahili, and two independent translators. Two days 
per week one interviewer each conducted interviews with HIV-seropositive women, while at 
the same time the other interviewer and the principal investigator (LFB) conducted 
participant observation at the CTC/VCTC.  
3.2 Study Participants and Recruitment Process 
Exclusively female patients 
were recruited by the AMOs, 
fulfilling the recruitment rules 
of being over 18 years of age, 
registered at the CTC, tested 
positive for HIV the earliest at 
the last visit of the CTC, being 
in a stable health condition to 
undergo the interview and prior 
to study commencement having 
provided written or finger-ink 
printed consent. A total of 104 
female women were asked for 
participation of which 62 
(59.6%) agreed. With one Figure 4: Recruitment of patients 
3. Methodology 
 12 
dropout prior to study commencement, a total of 61 women finally participated in the study, 
of whom 59 were enrolled on ART.  
For the publication attached and results presented within the chapters 4.2.3 and 4.2.4, only 
patients on ART were included in the data analysis (see Figure 4), while remaining results 
presented here include results from all 61 women interviewed.  
Following recruitment and verbal consent of participation, women were elucidated of the 
study in Kiswahili by the interviewer, were asked to give signed/finger-ink printed consent 
and received a copy of the signed clearance and consent form in Kiswahili prior to study 
commencement.  
3.3 Questionnaires for HIV-Seropositive Women  
A short questionnaire conducted by the AMO, using health-related information from the 
patient’s file taking approximately two minutes, followed a further pre-tested interviewer 
administered questionnaire in Kiswahili, containing a total of 34 questions and read out by 
the interviewer, taking approximately ten minutes. Questions focused on socio-demographic 
data, self-disclosure and adherence to ART and were adapted to the Tanzania setting. 14 
3.4 Ethnographic Qualitative Methods 
Following the questionnaires, a pre-tested standardized open-ended and audio-recorded 
interview followed, expanding upon the questions answered within the questionnaire.  
Furthermore, emphasis was placed on participant observation during the interview sessions 
and conducted by the prinicipal investigator. Aim was to document the patient’s look, facial 
expression and behavior during the interview session and the interaction between the 
interviewer and the interviewee, providing further information on their life and experience 
with the disease. Furthermore participant observation was conducted at the department by the 
research team, while numerous informal interviews and expert interviews were held.  
3.5 Processing of Data Material 
Interviews were directly transliterated after the interview session, using the open source 
audio-editor software Audacity 1.2.6a and the audio-transliteration software F4 for Microsoft 
Word. For transliteration slightly modified transcription rules designed by Kallmeyer and 
Schütze (1976; cit. in Mayring 1993) were in use. Two independent translators, fluent in both 
languages, translated the transliterated interviews from Kiswahili into English. Finally, the 
                                                 
14 The development of the questionnaire was influenced by studies focusing on disclosure and conducted in 
Tanzania in the past (e.g. Lie and Biswalo 1996), as well as inspired by Braun (2006) as preconditions in 
Tanzania – such as the school system – differ tremendously while The Allgemeine Bevölkerungsumfrage der 
Sozialwissenschaften (GESIS 2011; Eirmbter and Jacob 2000) could therefore not serve as a basis.  
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translation was proofread to secure validity of the translation and content discussed on a 
regular basis with the interviewers.  
The participant observation was silmultaneously paper-documented and typed on the same 




3.6 Data Analysis 
For further characterization of the women interviewed, questionnaires containing socio-
demographic and medical data were analyzed and frequencies calculated using SPSS 15.0 for 
Windows, with all figures rounded up to two decimal places.  
After general revision of the 61 interviews conducted with patients, content analysis was used 
for coding of the interviews and as defined by Flick (2007). After definition of main 
categories (= codes), such as self-disclosure, reactions to disclosure or ART adherence, 
further sub-categories were established, in particular by creating so called in-vivo codes, 
using terms verbally directly extracted from the interviews (Kuckartz 2005). Sub-codes were 
then deducted from main codes, such as the differentiation between different forms of 
reactions to disclosure. Finally, 
information deducted from the 
interviews were categorized and 
paraphrased “…through selection, 
deleting or bundling of codes” 
(Lissmann 2001, p. 71).  
For coding, the text analysis program 
MAXQDA Version 2 for Windows 
XP was used, offering an overview of 
data collected and simplifying 
transfer from coded material to 
SPSS.  
Before final coding of the interviews, 
inter-rater reliability was ensured 
with a cross-check conducted by an 
independent coder, coding >10% of 
the interview material, as 






Figure 5: Qualitative analysis of interviews (based on Mayring 
(2000, p. 4) and modified by LFB)  
3. Methodology 
 15 
A discussion of the results with the independent coder and optimization of the code guideline 
in use followed. The final code guideline was used for a new and overall coding of all 61 
patient interviews (see Figure 3). Coded interview material was analyzed and manually 
extracted, while for the publication attached data was transferred to SPSS for analyzation of 
frequencies of statements, allowing for the interpretation of the impact of statements given. 
Furthermore, data from the participant observation, relevant for the results presented here 
were manually extracted in order to provide further detailed information on the research 
setting, the circumstances and the women interviewed.  
Overall transliterated interview material amounts to more than 1,000 pages of data, with an 
additional 300 pages of documented participant observation.  
 
3.7 Methodological Approach of the M.A. Thesis in Comparison to the Medical 
Doctoral Thesis 
The above section refers to the methodological approach of the medical doctoral thesis and 
its publication in the African Journal of AIDS Research.  
Although the data analyzed and used for the publications derives from the same output data 
source, the thematic focus, methodological approach used for the M.A. thesis differs greatly 
in regard to the thematic topic, selection of data and analysis of data.  
The M.A. thesis focused on six selected interviews deriving from the output data while an 
ethnographic approach (through the use of qualitative and biographical data) was used. The 
qualitative data was supplemented by the analysis of five socio-demographic variables15 
originating from the 61 quantitative data sets (questionnaires only). Two diagrams16 and three 
tables17 present graphically the six interviews selected in clear distinction to the overall 
sample (n=61) in order to defend the selection process of the six interviewees portrayed. Six 
selected interviews were analyzed in detail using a qualitative approach and numerous direct 
citations embedded into participant observation were presented. 
For the medical dissertation a multiple-methodological approach was used, analyzing all 59 
interviews and questionnaires with HIV-seropositive women on ART. The quantitative data 
of all 61 women interviewed is presented, including all socio-demographic variables 
collected, the time since HIV-diagnosis, the time since ART commencement, receiving of 
counseling and adherence counseling and full, partial and non-disclosure in detail. Further, 59 
                                                 
15 The variables refer to age (“mean” only), religion (“frequency” only), education and ethnic origin (both in 
detail). 
16 Focusing on the religious affiiliation and education. 
17 Focusing on education, religion and ethnic origin. 
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interviews were analyzed using a quantitative and qualitative approach and through the 
quantification of qualitative findings.  
The analysis of the data was conducted separately and independently for both publications 
and also due to the different thematic foci. The analysis for the medical dissertation is 
described in detail above.  
In the frame of the M.A. thesis a total of 10 randomly selected interviews from the overall 
data set of 61 interviews were coded, in regard to the previously defined terms including 
“discrimination”, “stigmatization”, “illness” and “disease” and a code tree built. In-vivo 
codes, fact- and sub-codes were built. Following a total of 10% of the coded interview 
material was re-coded by an independent person to cross-check for inter-rater reliability. The 
code trees were compared and updated depending on the outcome of the two coding 
processes. Following the newly developed code tree was used and all 61 interviews coded 
again. In another step, a total of six interviews were chosen out of the pool of 61 interviews. 
The notes of the participant observation taken during these six interviews were also selected.  
As outlined in the M.A. thesis, “…(it) concentrates on the topic of discrimination and 
stigmatiziation in the context o illness and disease the topic of discosure was not analyzed 
here in particular although it was mentioned within the results where applicable and 






4.1 Results of the Questionnaire – Quantitative Data 
Within our study sample the age of women interviewed ranged between 22 years and 63 
years, with a mean age of 38.8 years and with a total of 44 women (74.6%) being of Muslim 
religion. Interviewees belonged to 20 different ethnic groups, with the Wasambaa (11 
women, 18.6%), Wadigo (10, 16.9%) and Wabondei (7, 11.9%) – originating in Tanga 
Region – representing the majority. 
The majority of women attended primary school in the past (n=46, 78.0% respectively), with 
again the majority working in the informal sector (n=27, 45.8%) or being unemployed and 
responsible for the household and the education of (their) child(ren) (n=18, 30.5%), with a 
mean monthly income of their household comprising of 35 Euro (52US$). The mean time of 
diagnosis among our interviewees was 1.9 years, with a maximum of 10.9 years and a 
minimum of 20 days.18 A total of 45 women could indicate the exact day of treatment 
commencement with a mean treatment time of 1.2 years.  
Prior to study commencement, an informal survey focusing on the adherence to ART among 
patients at the CTC with 14 members of the hospital staff at the HIV-department was 
conducted. The staff members were asked to voluntarily estimate the percentages of patients 
taking their ARVs regularly, and patients taking them irregularly. On average it was 
estimated that 80% of the patients took their medication regularly (max. 95%, min. 65%), 
with 20% taking them irregularly (max. 30%, min. 5%).19  
According to our findings, three interviewed women (5.2%) reported of having missed a dose 
within the last seven days, while 56 women (94.9%) have indicated of not having missed a 
dose within the last week prior to interviewing. When asked about overall adherence since 
the start of ART commencement, a total of 21 women (35.6%) told us of having missed at 
least one dosis since the start of treatment, while 37 women (62.7%) have not missed a dosis 
at all, with the answer missing of one participant.  
4.2 Interview Results – Qualitative Data 
Following, results of the 61 interviews conducted with female HIV-seropositive patients 
enrolled at the CTC concerning 1) the reactions to disclosure, 2) the perception of HIV and 
AIDS in an era of treatment availability, 3) reasons and strategies for ART adherence and 4) 
                                                 
18 For further detailed socio-demographic and medical information on the study sample, please see the 
publication attached. 
19 Regular intake was defined as taking them on a regular basis, without missing a single dosis.  
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the perception and impact of HAART onto the lives of infected will be briefly presented. To 
ensure fluency in reading, transliteration notes were obmitted within citations presented 
below. 
4.2.1 Reactions to Self-Disclosure  
Focusing on reactions to disclosure, three main categories evolved during content analysis 
and within statements given: First, women reported of experiences made, positively 
influencing their lives (58 women, 95.1%), such as receiving support. Second, interviewees 
mentioned experiences made, negatively influencing their lives (36 women, 59.0%), such as 
discrimination. Further experiences mentioned not suiting the two above categories were 
coded within the category of other reactions (32 women, 52.5% respectively).   
 
Positive reactions: Within the category of positive experiences, six major different reactions 
could be identified. Among these, seven different types of support as a reaction to verbal self-
disclosure were mentioned regularly by a total of 51 women (83.6%). One of our 
interviewees described her experiences resulting in disclosure the following:  
“They just took it as normal and they assist me when I have problems. (…) There is one 
aunt of mine even if I tell her today I have this problem she assists me (…). She is the 
one who helps me very much” (Interviewee 15, Section 88).20  
 
When one of the women interviewed disclosed to her grown-up children, they replied 
acceptingly “’Mama (it is) ok, it [i.e. HIV] is a worldwide trouble!’” (Interviewee 5, Section 
69).  
In particular, encouragement as a result of disclosure, was explicitly mentioned by 29 women 
(47.5%). As one woman, who informed immediate members of her family of origin, told us: 
“I guess they, they had suspicion before [i.e of me being infected with HIV]. (…) but 
they encouraged me and until now they are encouraging me” (Interviewee 06, Section 
58). 
 
During the interviews women told us that they were comforted by people having disclosed to, 
saying that HIV has become a normal disease (9 women, 14.8%) and should therefore be 
accepted (31 women, 50.8%). One of our interviewees disclosed to her maternal uncle 
(mjomba), informing him about problems she was suffering from due to infection and he 
replied the following:  
                                                 
20 Within this thesis direct citations contain round brackets (…) indicating that text was omitted, round brackets 
with text, supplementing the sentence for a better understanding and square brackets, directly relating to a 
specific word or wording in the text for clarification.  
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 “’It is normal my daughter, do not be worried. These are things which are seen among 
all of the people’. Then I found them normal, because when I come here at the hospital 
usually I find a lot of the people [i.e. at the CTC being infected with HIV] and I get 
hope” (Interviewee 11, Section 44). 
 
Although the majority of the women experienced some sort of discrimination, 22 women 
(36.1%) also explicity told us, that they were not discriminated by the people they have 
disclosed to, as mentioned by this interviewee: 
“My relatives received me just well. They did not discriminate me to this minute. They 
refused even (me being) in the kitchen. I do not cook now. ‘Our fellow is sick, leave 
her!’ (they say). Honestly, I thank them!” (Interviewee 20, Section 89).  
 
Apart from support21 and encouragement, 34 women (55.7%) mentioned receiving advise 
from others following verbal self-disclosure, with only one woman directly mentioned 
empathy (1.6%). 
 
Negative reactions: Among this category, eight major different negative reactions were 
identified among the interviews conducted and analyzed. Within the category of emotions, a 
total of four different emotions experienced were reported by a total of 22 women (36.1%). 
Among them sadness was a common expression among significant others informed of a 
woman’s HIV-seropositive status (18 women, 29.5%). As one of our interviewees told us:  
“(…) they were sad. Many have cried a lot for me, many have cried a lot until they 
adviced me ‘Thank God, it [i.e. HIV] is a normal thing. Do not think too much!’” 
(Interviewee 42, Section 158).  
 
Five women (8.2%) also experienced denial, as one of our interviewees described the 
reaction of her husband: “Until now my husband does not believe that I am infected, do you 
understand? But we talk and laugh (…)” (Interviewee 3, Section 234).  
Further reactions to disclosure depicted by the interviewees were angriness (4 women, 6.6%), 
accusation (4 women, 6.6%), separation (1 woman, 1.6%) and the need to move out of the 
house (8 women, 13.1%). One of our interviewees described the reaction after disclosure by 
her mother and the younger sister of her mother (mama mdogo) the following:  
“They were angry. (...) They asked where did I get the problems [i.e. being HIV-
seropositive] from. Then they calmed down“ (Interviewee 4, Section 131 and 133).  
 
Furthermore one interviewee (1.6%) experienced her husband demanding for a proof of being 
infected, while a total of six women (9.8%) were commanded not to disclose further, as 
stated by one woman: “I was unhappy. The fact that my husband told me I should not tell 
                                                 
21 Within the interviews women differentiated between general support, health support, economic support, 
emotional support or any other type of support. 
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anybody gave me a headache” (Interviewee 3, Section 218) and “I was afraid of my husband 
because he didn’t want anybody to know” (Interviewee 3, Section 205).  
Additionally, 11 women (18.0%) reported of various forms of massive discrimination directly 
in connection with revealing their HIV-seropositive status, in particular by non-relatives, 
such as neighbors, their partner’s family or their partners. As one of the women told us: “(…) 
my step-mother and me we were not getting along. She didn’t want me. She was 
discriminating me a lot“ (Interviewee 27, Section 38).  
 
Other reactions: Furthermore, seven different reactions could be identified, not suiting the 
two categories above, mentioned by 32 women (52.2%). People were surprised (2 women, 
3.3%) or felt frail (3 women, 4.9%). As one interviewee said: “I guess they, they had 
suspicion before [i.e. of me being infected with HIV]. They were shocked, they were shocked 
to some instance (…)” (Interviewee 06, Section 58). 
Others went testing themself (14 women, 23.0%) or asked for advice (2 women, 3.3%), while 
again others answered that the diagnosis could not be changed (6 women, 9.8%), as described 
by one of our interviewees when disclosing to her son who answered: “(...) ‘Mom it has 
happened already what should we do? It is a normal disease (which can happen) to every 
human being!’“ (Interviewee 45, Section 158). Again others experienced no reaction at all (2 
women, 3.3%) as one of of the women interviewed described: “Well, when I told my mother 
she did not say anything, she just kept quiet“ (Interviewee 60, Section 95).  
4.2.2 The Conceptualization of HIV and AIDS among HIV-Seropositive Women at the CTC 
During the interviews conducted the term normal (kawaida) was significantly frequently used  
(347 times) by our interviewees in connection with HIV and AIDS, with 10 different 
categories evolving in the context of reactions to disclosure. One of our interviewees 
described the reactions by her relatives after disclosure the following:  
“They took it as it is. They told me not to think about it all the time, not to loose hope, 
because it is a normal thing. Anyone may get HIV. I should not get worried and loose 
hope. I then accepted their advice” (Interviewee 10, Section 29; emphasis LFB).   
 
However, being HIV-seropositive was not only interpreted as being normal (reported by 29 
women, 47.5%) by immediate family members of origin chosen for self-disclosure, but in 
particular by the patients themselves (31 women, 50.8%). As one of our interviewees 
answered, when asked about her experienced reactions to disclosure: “(…) the problem is 
that there is no cure for this [i.e. disease]. (…) but right now it [i.e. being infected with HIV] 
has become normal” (Interviewee 9, Section 97-98; emphasis LFB). And another interviewee 
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stated: “I now see it [i.e. being HIV-seropositive] just normal. HIV/AIDS is a normal 
problem” (Interviewee 12, Section 20; emphasis LFB).  
Reasons for these assumptions where manifold. First, a total of seven interviewees (11.5%) 
said that the destiny of becoming infected with HIV could affect anybody, hence leading to 
normality, as argued by one of the woman: “I felt normal because I knew there is such an 
epidemic and this disaster could happen to anybody else” (Interviewee 5, section 4; emphasis 
LFB). Second, the high number of people infected led to the assumption of HIV and AIDS 
being normal (11 women, 18.0%).  
One of our interviewees described her disease perception before receiving adherence classes 
the following: “(…) I knew when you get that problem [i.e. HIV and AIDS] perhaps that’s 
the end of life” (Interviewee 12, Section 17). However, after attending the classes at the CTC 
she told us that she realized “(…) a lot of people are infected. To me these are like normal 
things nowadays” (Interviewee 11, Section 8; emphasis LFB). And another woman told us:  
“That sister of mine also said it is only that some of us have not get tested but we are all 
infected, the whole of Tanga! But it is only that we have not gone to get tested, but we 
are infected!” (Interviewee 34, Section 131).  
 
Third, the high number of people infected with HIV again led to comparisons with often 
occurring diseases as reported by one woman as a direct reaction to disclosure. She told us:  
“(…) this [i.e. HIV] is a normal thing, it can occur to anybody. Let us say it is like Malaria 
for people now” (Interviewee 34, Section 131; emphasis LFB). And fourth, although HIV 
was known as being incurable among our interviewees, women now had the possibility to 
actually treat their disease with medication, leading to a normalization and change in 
perception of the disease as indicated by 6 women (9.8%).  
4.2.3 Reasons and Strategies to ART Adherence 
Throughout the literature no universal definition for adherence to ART exists and several 
methods for measurement are in use. Overall, studies measuring the outcome of adherence 
are focusing on missed doses, exceeding pill taking and/or the timing of dosage taking. In 
general, measurement is conducted by self-report and missed dosis over a certain time period, 
pill count, refill records, or proportion measurement through electroning monitoring advice 
(Simoni et al. 2003) or plasma levels of HIV-1 ribonucleid acid (RNA) (equaling the viral 
load level).  
The National Guidelines for the Clinical Management of HIV/AIDS, distributed to the AMOs 
and developed by the National AIDS Control Programme (NACP) on behalf of the Tanzanian 
Ministry of Health (MoH) does not provide a clear-cut definition of optimal adherence. 
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However, and according to the guidelines, ideally adherence “(…) rates > 95% (should be 
obtained) to maximize the benefits of ART” (MoH 2005).  
During the adherence-classes held at the CTC optimal adherence was defined as taking the 
medication regularly, without missing a pill and with exactly 12 hours between the first 
dosage in the morning and second dosage in the evening. If more than 30 minutes had passed 
according to the actual pill taking patients were advised to skip the dosage. However, and 
according to our knowledge, no universal definition of adherence existed at the department. 
Pharmacist defined non-adherence by patients as not taking their medication regularly and 
missing more than a full day of pill taking, or having left over pills of more than two days. 
When we asked interviewees about their adherence rates, women recited precisely on what 
they had learned in the adherence classes.  
 
During our interviews women showed manifold strategies (12 different strategies in total) in 
order to ensure adherence to antiretroviral treatment. First, women indicated numerous 
reasons, which helped them to generally adhere. While some women indicated the education 
of the importance of optimal adherence received at the CTC as the reasons to be adherent (7 
women, 11.5%), others indicated the need to obey to what the doctors say (21 women, 
34.4%). However, a connotation of fear resonated within both factors mentioned. One 
woman justified her being adherent the following: 
„(...) I was informed that with this drug it is not allowed to miss even a single day, or 
fail to follow the hours. Because when you delay or fail then you are causing resistance 
to those viruses. That is why you need to be careful at any time, because you must 
swallow at that time and a day should not pass without swallowing“ (Interviewee 24, 
Section 143).  
 
Another interviewee told us:  
“I am afraid since we have been told that failing to take the dosage for only one day the 
virus then starts to emerge [i.e. multiply]. When you have taken it, it sleeps. It does not 
die, but it is sleeping“ (Interviewee 34, Section 26).  
 
A total of 17 women (27.9%) indicated that their life depends on regular drug taking. Women 
also reported their religious faith as a reason to take the medication regularly (8 women, 
13.1%). Furthermore, sickness prior to ART commencement (6 women, 9.8%), the fear of 
recurring sickness (1 woman, 1.6%) and a stable health condition (6 women, 9.8%) since 
therapy was indicated as a reason for following the treatment plan. One interviewee 
explained her reason for being adherent the following: “It is because in the past I was very 
sick. That is why I can not stop taking the medications“ (Interview 8, Section 27). Another 
woman argued her not forgetting the dose saying: „(...) because I want to live! I know if I 
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stop or forget to take my medication then someday a problem will happen“ (Interviewee 101, 
Section 480).  
Additionally, being used to taking the medication regularly (8 women, 13.1%) and carrying 
them whereever they go (8 women, 13.1%), helped in securing general adherence.  
 
Strategies in order to remember regular dosage taking were manifold (10 in total). While 
many women (31 women, 50.8%) were supported by people, helping to remember to take 
their dosage on time, many had a watch (12 women, 19.7%), a mobile phone (5 women, 
8.2%) or an alarm clock or a radio (7 women, 11.5%) to remember them of their time of pill 
taking. However, few (2 women, 3.3%) indicated taking them before their daily activity or a 
certain meal, while again few followed either the prayer of the Muazzin (3 women, 4.9 %) or 
the sunrise and sunset (2 women, 3.3%) as a substitute to remember and take ART regularly. 
Again two women (3.3%) remembered their regular dosage taking by writing in a book, 
while one interviewee (1.6%) mentioned to always take her dosage after her having a meal. 
4.2.4 The Perception and Impact of HAART  
Many women (13 women, 21.3%) felt thankful for treatment availability, and expressed relief 
(1 woman, 1.6%) or hope (15 women, 24.6%). As one woman told us: 
„As I told you, I would have died because of this problem at any time, while after given 
treatment [i.e. ARVs] days are moving on. In addition, when you follow the regular 
treatment schedule you may reach the age God has planned. We thank those who 
discoverd these drugs!“ (Interviewee 10, Section 114).  
 
Interviewees also reported of a dramatic health improvement (38 women, 62.3%) and a 
positive change in life (13 women, 21.3%), as well as a new independence gained due to a 
better health condition (3 women, 4.9%). As one woman said: “I thank God they [i.e. ARVs] 
have helped me. Until now I can walk by myself! I come alone to the hospital. Previously, 
my mother had to bring me.“ (Interviewee 17, Section 171).  
However, four women (6.6%) told us of their fear coming along with the medication and 
others of rumors about people suddenly dying due to ART (2 women, 3.3%). Furthermore, 
one woman (1.6%) experienced forced disclosure, while nine women (14.8%) reported of 
discrimination due to the possession, picking or taking of medication or their sudden health 
improvement being questioned by others. The fear of involuntary disclosure also led to the 
need of lying (14 women, 23.0%), as described by one of our interviewees, when asked 
whether she tells her neighbors that she is going to the CTC to pick up her medication:  
„The ones I tell [i.e. of going to the CTC] are my father, my mother and my children. 
But how will a neighbour help me even if I tell (him/her)? Mostly it is to announce that 
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(I am) infected which does not help me. I stay with them [i.e. my neighbors] inside [i.e. 
in the same house] there but I have not revealed even one of my secrets. Today I have 
left (to come to the CTC), telling them that I am going to have my tooth extracted since 
the day before yesterday I had a toothache. (...) what will a neighbour help me with, 
rather than announcing after I have told him/her? He/she will just announce me. 
Wherever you will stay, you will not be happy. ‘She is already infected with the HI-
Virus’ (they will say).” (Interviewee 28, Section 60).  
 
And another interviewee says: „I tell them I just feel to have fever. I am using malaria 
medications or something else. That is all. I do not disclose so much“ (Interviewee 11, 
Section 150).  
Furthermore, women reported hiding of pill taking (21 women, 34.4%), picking (18 women, 
29.5%) or storing them (17 women, 27.9%), in order not to be involuntarily disclosed due to 
the possession of medication, as described by one interviewee when asked where she stores 
her medication: “(I store them) in a plastic bag. Then I hide it under the bed because there it 
is not possible for anybody to see it“ (Interviewee 8, Section 26).  
And another women told us: 
 
„(In) our home (...) we are a lot of people. Somebody will get in and will start looking 
around. ‘What are these bottles here for? Give them to me so that I can store something 
in them!’ (...) That is why now I use to hide them and if I finish [i.e. the pills] I look for 
a place and burn it [i.e. the bottle] or I throw it somewhere so that nobody knows“ 
(Interviewee 34, Section 14).22  
 
4.3 Results of the M.A. Thesis in Comparison to the Medical Doctoral Thesis 
The M.A. thesis describes in detail the numerous experiences by the selected women related 
to discrimination and their HIV-status. Self-discrimination has only been rarely described by 
the women interviewed. Overall the influene of the hospital setting was apparent while 
biomedical terms (such as CD4 Count) were frequently used by the six women portrayed. 
Several explanatory approaches related to their disease and illness existed interchangeably 
while God and believing in God played a major role related to their destiny and disease. 
Furthermore, the normalization of HIV – referred to as “normal” – played a prominent role as 
a potential coping strategy. 
 
The medical doctoral thesis focuses on rates, patterns and reasons in relation to disclosure of 
the HIV-seropositive status. All HIV-seropositive women interviewed had partially disclosed 
their HIV-satus while the majority has disclosed to more than one person. In comparison to 
                                                 
22 At the time of data collection the plastic containers with ARVs were highly visibly labeled with the 
medication name and – depending on the brand – a red ribbon flag, widely known in Tanzania as a symbol for 
HIV and AIDS.   
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previous studies women disclosed to more people - almost a quarter however did not inform 
their husband. The major reason for disclosure was the hope for support. Also antiretroviral 
therapy was mentioned frequently as a reason, which has not been thematized in previous 
publications.  
HIV-seropositive women in Tanzania are confronted with numerous challengs related to their 
disclosure due to socio-economic dependency. Interviewed women were deeply dependent on 
the hospital setting and its staff, and recommendations as well as pressure by the care takers 
have influenced their decisions related to disclosure. Despite the availability of antiretroviral 






Prior to access to treatment, reactions to disclosure have been researched within Sub-Saharan 
Africa, Southeast Asia, the USA and Western Europe, as summarized by reviews conducted 
by Medley et al. (2004) and the WHO (2003b).  
Within the United Republic of Tanzania only few studies have focused particularly on the 
outcomes of self-disclosure prior to universal access to treatment (Kilewo et al. 2001; Maman 
et al. 2003). However, these studies have concentrated on reactions to partners only with 
positive reactions significantly exceeding those of negatives. Since the availability of 
treatment, again only few studies have been conducted in Tanzania (Greeff et al. 2008; 
Lugalla et al. 2008; Moyer 2012; Bohle 2013; Bohle et al. 2014), with an emphasis on 
negative reactions to self-disclosure.  
Within this summary we could present unique and detailed information on negative, positive, 
as well as further reactions experienced by HIV-seropositive women in Tanzania following 
disclosure. Noticeably, and despite ART, results resembled those of studies conducted prior 
to ART availability. However, results are of great interest when it comes to women reporting 
of massive discrimination experienced in particular by non-relatives following self-diclosure 
and despite treatment availability.  
As can be seen from our results and confirmed by the TACAIDS et al. (2008), the 
expectation raised with the implementation of universal access to treatment, leading to a 
massive decrease of discrimination within the community has not come true. In the contrary 
and according to informal interviews with staff from the Deutsche Gesellschaft für 
Internationale Zusammenarbeit (GIZ) in Dar es Salaam and the BRH hospital staff in October 
2013, discrimination due to HIV-infection in Tanzania remains high. Nevertheless, since 
treatment availability reactions to disclosure experienced by our interviewees differed and 
were not solely negative as presented by the studies previously conducted by Greeff et al. 
(2008) and Lugalla et al. (2008).  
 
With the availability of ART a change in disease perception developing from a deadly to a 
chronic and treatable disease was anticipated by advocaters of universal access to treatment. 
As could be observed by Roura et al. (2009), this development has taken place among HIV-
seropositive patients registered at a CTC in Northern Tanzania, with a normalization of HIV 
seem to have occurred. Roura et al. (2009) analyzed numerous reasons leading to the process 
of normalization, with some reasons revealed resembling our results. However, within our 
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results we could identify further unique reasons leading to a normalization of HIV among 
HIV-seropositive clients at the hospital setting enrolled on ART. Apart from meeting 
innumerable infected people at the CTC, the high prevalence of HIV among the surrounding 
population and the high number of families affected, as well as the possibility of treatment 
might have led to the perception of HIV being a normal disease. Furthermore, women were 
elucidated of different possible modes of infections taught at adherence classes at the CTC, 
such as sexual intercourse, physical injury or nursing, possibly leading to the assumption of 
HIV being a normal disease, as it could be easily acquired and was seen as a destiny that 
could affect anybody, as mentioned by our interviewees.  Results presented here show an 
unexpected disease perception, which can be explained the following: first, with the 
development of coping strategies possibly leading to a reduction of self-stigma among 
PLWHA. And second, with the influence of hospital staff on shaping opinions, as outlined by 
Mattes (2011; 2014). The perceptions expressed are promising but at the same time alarming, 
in regard to prevention of further transmission. The process of normalization in the context of 
HIV and AIDS and free antiretroviral treatment needs to receive further attention in future 
research, not only among people infected but also among the overall Tanzanian population.  
 
Despite opponants’ doubts, studies certify high adherence rates among PLWHAs enrolled on 
ART in resource-poor settings. However, reasons and strategies fostering optimal adherence, 
as well as perceptions and impact of ART onto the lives of infected since treatment 
availability remain mostly unknown.  
Results concerning reasons for adherence to ARVs among patients enrolled on ART in 
Tanzania have been published by Watt et al. (2009). While most results resembled our 
findings, further insights into reasons supporting adherence to ART mentioned by our 
interviewees, such as faith, the medical knowledge of the importance of optimal adherence, 
as well as fear of (recurring) sickness were presented here. Furthermore unique data on the 
impact of ART onto the lives of infected within the Tanzanian setting were highlighted. 
While interviewees reported of improved health conditions, relief and hope in connection 
with ART, women also had to bear challenges coming along with treatment, such as avoiding 
involuntary disclosure and discrimination due to medication.   
However, the study contains several limitations. First, a relatively small number of patients 
(n=61, and n=59 respectively) were interviewed, leading to a restriction of generalizations. 
Second, with exclusively female patients interviewed, gender-specific comparisons between 
clients could not be drawn, while future studies should possibly include both, men and 
women. Third, results presented here need to be seen as context-specific and demand 
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cautious interpretation as the study was solely conducted in a clinically based setting. For 
possible generalizations of results further extensive ethnographic studies within the 





6. Conclusion  
With the implementation of universal access to treatment great hope was raised concerning a 
change of disease perception, hence leading to a decrease in “(…) denial, stigma and 
discrimination…” (WHO 2003a, p. 6) as outlined above. As can be seen from the results, 
these hopes were only fulfilled to some extent. With the implementation of ART an 
expressed normalization of HIV among our patients visiting the hospital could be observed. 
However, it needs to be presumed that several factors – such as the high prevalence rate, a 
high number of people directly or indirectly affected, mandatory counseling prior to ART 
commencement – and apart from the availability of ART, lead to the expressed process of 
normalization of HIV. As these results are context-specific, this development can be 
interpreted as a pleasant development in regard to a decrease in self-stigmatization and 
coping with the disease among people infected with HIV. However, at the same time this 
process is also highly alarming with regard to prevention of further transmission. It needs to 
be investigated in future studies, whether the expressed perception actually translates into 
lived actions and if so to which extent. While this development asks for close observation in 
the future, further research within the communities is urgently needed.  
Nevertheless, results can lead to the cautious assumption that despite treatment availability, a 
reconceptualization of HIV among the general community does not seem to have occurred, 
with levels of discrimination in the context of HIV and AIDS among the overall community 
remaining high in Tanzania, as confirmed by informal interviews in Tanzania in 2013.  
With positive outcomes coming along with ART, such as a stabilization of health, hope and 
relief, ART also bears great challenges imposed upon people infected and their respective 
environment, such as discrimination due to pill taking and the fear of involuntary disclosure. 
Hence, the social support for people infected and their environment is more than ever of 
urgent need and greatly missing. Knowledge of the social impact of ART – such as the 
process and outcome of disclosure, the perception of HIV and AIDS and the effects of ART – 
is of crucial importance for future public health interventions in regard to the planning of 
prevention and support programs for people enrolled on ARVs.  
Since the implementation of (universal) access to treatment, the social impact of ART has 
been significantly neglected, while further multi-methodological research, providing detailed 
and culturally adapted results in the future and a debate on the social impact of the 





Attaran A (2007): Adherence to HAART: Africans Take Medicines More Faithfully than 
North Americans. PLoS Med 4, E83 
Baltazary G, Akarro RRJ, Mussa AS (2011): Some factors associated with non-adherence to 
antiretroviral therapy (ART) in people living with HIV/AIDS (PLHA) in Tanzania: a 
case study of Dar es Salaam region. East Afr J Public Health 8, 237–246 
Bohle LF: Stigmatization, Discrimination and Illness: Experiences among HIV-Seropositive 
Women in Tanga, Tanzania. Magisterarbeit (M.A. thesis) Göttingen 2011 
Bohle LF: Stigmatization, Discrimination and Illness: Experiences among HIV-Seropositive 
Women in Tanga, Tanzania. 1st edition; Universitätsverlag Göttingen, Göttingen 2013 
Bohle LF, Dilger H, Groß U (2014): HIV-serostatus disclosure in the context of free 
antiretroviral therapy and socio-economic dependency: experiences among women 
living with HIV in Tanzania. Afr J AIDS Res 13, 215–227 
Braun M: Funktionale Äquivalenz in interkulturell vergleichenden Umfragen. Mythos und 
Realität. ZUMA, Habil.-Schrift Mannheim 2006 
De Klerk J (2012): The compassion of concealment: silence between older caregivers and 
dying patients in the AIDS era, northwest Tanzania. Cult Health Sex 14, 27-38 
Deribe K, Woldemichael K, Wondafrash M, Haile A, Amberbir A (2008): Disclosure 
Experience and Associated Factors among HIV Positive Men and Women Clinical 
Service Users in Southwest Ethiopia. BMC Public Health 8 
Dilger H: Leben mit Aids. Campus, Frankfurt am Main [a.o.] 2005 
Dlamini PS, Wantland D, Makoae LN, Chirwa M, Kohi TW, Greeff M, Naidoo J, Mullan J, 
Uys LR, Holzemer WL (2009): HIV stigma and missed medications in HIV-positive 
people in five African countries. AIDS Patient Care STDS 23, 377–387 
Donnelly J (2001): Prevention urged in AIDS fight Natsios says fund should spend less on 
HIV treatment. Boston Globe, June 7, 2001 
Eirmbter WH, Jacob R: Allgemeine Bevölkerungsumfragen. Oldenbourg, München [u.a.] 
2000 
Flick U: Qualitative Forschung : ein Handbuch. 5th edition; Rowohlt-Taschenbuch-Verl., 
Reinbek bei Hamburg 2007 
Gari T, Habte D, Markos E (2010): HIV positive status disclosure to sexual partner among 
women attending ART clinic at Hawassa University Referral Hospital, SNNPR, 
Ethiopia. Ethiop J Health Dev 24, 9-14 
GESIS: Die Allgemeine Bevölkerungsumfrage der Sozialwissenschaften, ALLBUS: Die 




Gielen A, OCampo P, Faden R, Eke A (1997): Women’s disclosure of HIV status: 
Experiences of mistreatment and violence in an urban setting. Women Health 25, 19-
31 
Giles L: Spirit possession on the Swahili coast: Peripheral cults or primary texts?, Ph.D. 
Diss.:, Austin, 1989 
Greeff M, Phetlhu R, Makoae LN, Dlamini PS, Holzemer WL, Naidoo JR, Kohi TW, Uys 
LR, Chirwa ML (2008): Disclosure of HIV Status: Experiences and Perceptions of 
Persons Living with HIV/AIDS and Nurses Involved in Their Care in Africa. Qual 
Health Res 18, 311-324 
Hardon A, Dilger H (2011): Global AIDS Medicines in East African Health Institutions. Med 
Anthropol 30, 136-157 
Hardon AP, Akurut D, Comoro C, Ekezie C, Irunde HF, Gerrits T, Kglatwane J, Kinsman J, 
Kwasa R, Maridadi J et al. (2007): Hunger, waiting time and transport costs: time to 
confront challenges to ART adherence in Africa. AIDS Care 19, 658-665 
Irunde H, Nsimba SED, Comoro CJ (2009): Need for improving quality of operating 
structures and processes for better ARV adherence for patients with HIV/AIDS in 
Tanzania and other African countries: An experience from Tanzania. Asian Pac J 
Trop Med 2, 67-74 
Ivers LC, Kendrick D, Doucette K (2005): Efficacy of Antiretroviral Therapy Programs in 
Resource‐Poor Settings: A Meta‐analysis of the Published Literature. Clinical 
Infectious Diseases 41, 217-224 
Kallmeyer W, Schütze F: Studium Linguistik, 1: Konversationsanalyse. Scriptor Verlag, 
Kronberg/Taunus 1976 
Keogh P, Allen S, Almedal C, Temahagili B (1994): The Social Impact of HIV-Infection on 
Women in Kigali, Rwanda: A Prospective Study. Soc Sci Med 38, 1047-1053 
Kilewo C, Massawe A, Lyamuya E, Semali I, Kalokola F, Urassa E, Giattas M, Temu F, 
Karlsson K, Mhalu F, Biberfeld G (2001): HIV Counseling and Testing of Pregnant 
Women in Sub-Saharan Africa: Experiences from a Study on Prevention of Mother-
to-Child HIV-1 Transmission in Dar Es Salaam, Tanzania. J AIDS 28, 458-462 
Kuckartz U: Einführung in die computergestützte Analyse qualitativer Daten. 1st edition; VS 
Verlag für Sozialwissenschaften, Wiesbaden 2005 
Langwick SA: Bodies, Politics, and African Healing: The Matter of Maladies in Tanzania. 
Indiana University Press, Bloomington, 2011 
Lie GT, Biswalo PM (1996): HIV-positive patient’s choice of a significant other to be 
informed about the HIV-test result: Findings from an HIV/AIDS counselling 
programme in the regional hospitals of Arusha and Kilimanjaro, Tanzania. AIDS Care 
8, 285-296 
Lissmann U: Inhaltsanalyse von Texten. (Forschung, Statistik & Methoden), 2nd expanded 
and updated edition; Verl. Empirische Pädagogik, Landau 2001 
7. Bibliography 
 32 
Lugalla JLP, Madihi CM, Sigalla HL, Mrutu NE, Yoder PS: Social Context of Disclosing 
HIV Test Results: HIV Testing in Tanzania. (DHS Qualitative Research Studies 15); 
Dar es Salaam, Tanzania: Centre for Strategic Research and Development and 
Calverton, Maryland, USA: Macro International Inc., 2008. 
http://pdf.usaid.gov/pdf_docs/PNADO437.pdf [23.08.2015] 
Lyimo RA, de Bruin M, van den Boogaard J, Hospers HJ, van der Ven A, Mushi D (2012): 
Determinants of antiretroviral therapy adherence in northern Tanzania: a 
comprehensive picture from the patient perspective. BMC Public Health 12, 716 
Lyimo RA, Stutterheim SE, Hospers HJ, de Glee T, van der Ven A, de Bruin M (2014): 
Stigma, disclosure, coping, and medication adherence among people living with 
HIV/AIDS in Northern Tanzania. AIDS Patient Care STDS 28, 98-105 
Mackenrodt L: Swahili Spirit Possession and Islamic Healing in Contemporary Tanzania. 1st 
edition; Dr. Kovač, Hamburg 2011 
Makoae LN, Portillo CJ, Uys LR, Dlamini PS, Greeff M, Chirwa M, Kohi TW, Naidoo J, 
Mullan J, Wantland D, et al. (2009): The impact of taking or not taking ARVs on HIV 
stigma as reported by persons living with HIV infection in five African countries. 
Aids Care-Psychol Socio-Med Asp Aids-Hiv 21, 1357-1362 
Maman S, Mbwambo J, Hogan NM, Weiss E, Kilonzo GP, Sweat MD (2003): High Rates 
and Positive Outcomes of HIV-Serostatus Disclosure to Sexual Partners: Reasons for 
Cautious Optimism from a Voluntary Counseling and Testing Clinic in Dar es 
Salaam, Tanzania. AIDS Behav 7, 373-382 
Mattes D (2011): „We are just supposed to be quiet“: the production of adherence to 
antiretroviral treatment in urban Tanzania. Med Anthropol 30, 158-182 
Mattes D (2014): Caught in transition: the struggle to live a „normal“ life with HIV in 
Tanzania. Med Anthropol 33, 270-287 
Mayring P: Einführung in die qualitative Sozialforschung. 2nd expanded edition; Beltz, 
Weinheim 1993 
Mayring P (2000): Qualitative Content Analysis. Qualitative Social Research 1. 
http://www.qualitative-research.net/index.php/fqs/article/view/1089 [23.08.2015] 
Mberesero F: Personal interview with Dr. Firimina Mberesero, founder of TAWG, Tanga 
City, 08. August 2008  
Médecins Sans Frontières (MSF): A Matter of Life & Death: The Role of Patents in Access 
to Essential Medicines, 2001. https://www.msf.org/sites/msf.org/files/doha_11-
2001.pdf [23.08.2015] 
Medley A, Garcia-Moreno C, McGill S, Maman S (2004): Rates, barriers and outcomes of 
HIV serostatus disclosure among women in developing countries: implications for 




Mills EJ, Nachega JB, Bangsberg DR, Singh S, Rachlis B, Wu P, Wilson K, Buchan I, Gill 
CJ, Cooper C (2006a): Adherence to HAART: A Systematic Review of Developed 
and Developing Nation Patient-Reported Barriers and Facilitators. PLoS Med 3, e438 
Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, Rachlis B, Wu P, Cooper C, 
Thabane L, et al. (2006b): Adherence to antiretroviral therapy in sub-Saharan Africa 
and North America: a meta-analysis. JAMA 296, 679-690 
Ministry of Health (MoH): National Guidelines for the Clinical Management of HIV/AIDS – 
Tanzania, National AIDS Control Programme (NACP), Dar es Salaam, 2005. 
http://collections.infocollections.org/whocountry/en/d/Js6885e/12.7.html [23.08.2015] 
Moyer E (2012): Faidha gani? What’s the point: HIV and the logics of (non)-disclosure 
among young activists in Zanzibar. Cult Health Sex 14 Suppl 1, 67-79 
Mutume G (2001): Health and „intellectual property“. Africa Recovery 1-2, 14 
National Bureau of Statistics (NBS) (2002): Household Budget Survey 2000/01: Key 
Findings. NBS, Dar Es Salaam 2002. 
http://catalog.ihsn.org/index.php/catalog/89/download/28732 [23.08.2015] 
Neumann M: South Africa. MSF, an African NGO? In: Humanitarian negotiations revealed: 
the MSF experience. Hurst, London 2011, 163-170. http://www.msf-
crash.org/livres/en/book/export/html/1602 [23.08.2015] 
Paterson D, Swindells S, Mohr J, Brester M, Vergis E, Squier C, Wagener M, Singh N 
(2002): Adherence to protease inhibitor therapy and outcomes in patients with HIV 
infection. Ann Intern Med 136, 253-253 
Pemba SK: Training of Assistant Medical Officers in Tanzania, 2008. 
http://www.healthtrainingifakara.org/fileadmin/user_upload/healthtrainingifakara/pdf/
Assistant_Medical_Officer_Course_Profile_01.pdf [23.08.2015] 
(PEPFAR:) The United States President’s Emergency Plan for AIDS Relief (PEPFAR) 
(2012): Partnership to Fight HIV/AIDS in Tanzania.  
http://www.pepfar.gov/documents/organization/199593.pdf [23.08.2015] 
Ramadhani HO, Thielman NM, Landman KZ, Ndosi EM, Gao F, Kirchherr JL, Shah R, Shao 
HJ, Morpeth SC, McNeill JD, et al. (2007): Predictors of incomplete adherence, 
virologic failure, and antiviral drug resistance among HIV-infected adults receiving 
antiretroviral therapy in Tanzania. Clin Infect Dis 45, 1492-1498 
Rosenthal G: Interpretative Sozialforschung. 2nd corrected edition; Juventa-Verl., Weinheim 
[a.o.] 2008 
Roura M, Wringe A, Busza J, Nhandi B, Mbata D, Zaba B, Urassa M (2009): „Just like 
fever“: a qualitative study on the impact of antiretroviral provision on the 
normalisation of HIV in rural Tanzania and its implications for prevention. BMC Int 
Health Hum Rights 9, 22-22 
Simoni JM, Mason HR, Marks G, Ruiz MS, Reed D, Richardson JL (1995): Women’s self-




Simoni JM, Frick PA, Pantalone DW, Turner BJ (2003): Antiretroviral adherence 
interventions: a review of current literature and ongoing studies. Top HIV Med 6, 
182-198 
Tanga AIDS Working Group (TAWG): Tanga Aids Working Group: Update Paper. TAWG, 
Tanga 2010 
(TACAIDS:) Tanzanian Comission for AIDS (TACAIDS) (2009): The History, Trends of 
Prevalence, and Efforts towards Prevention and Control of HIV and AIDS in the Last 
25 Years in Tanzania Mainland from 1983-2009. 
http://www.tacaids.go.tz/index.php?option=com_docman&task=doc_download&gid=
23&Itemid=142. [23.08.2015] 
(TACAIDS:) Tanzanian Comission for AIDS (TACAIDS), Zanzibar AIDS Commission 
(ZAC), National Bureau of Statistics (NBS), Office of the Chief Government 
Statistician (OCGS), Macro International Inc.: Tanzania HIV/AIDS and Malaria 
Indicator Survey 2007-08. TACAIDS, ZAC, NBS, OCGS, and Macro International 
Inc., Dar es Salaam 2008. dhsprogram.com/pubs/pdf/ais6/ais6_05_14_09.pdf 
[23.08.2015] 
The United Republic of Tanzania (2006): Census 2002: Analytical Report, Volume X. 
National Bureau of Statistics (NBS) and Ministry of Planning, Economy and 
Empowerment, Dar es Salaam. August 2006. 
http://www.nbs.go.tz/takwimu/references/2002popcensus.pdf [23.08.2015] 
Thielman NM, Ostermann J, Whetten K, Whetten R, Itemba D, Maro V, Pence B, Reddy E, 
CHAT Research Team (2014): Reduced adherence to antiretroviral therapy among 
HIV-infected Tanzanians seeking cure from the Loliondo healer. J Acquir Immune 
Defic Syndr 65, e104-109 
Treatment Action Campaign (TAC): About the Treatment Action Campaign, 2015. 
http://www.tac.org.za/community/about [23.08.2015] 
UNAIDS (2008): The HIV epidemic in Tanzania Mainland: Where have we come from, 
where is it going, and how are we responding? – ‘Tunakotokea, tunaelekea wapi na 
tunachokifanya ni nini?’: Final report: 6 November 2008. Report prepared by ASAP, 
a service of UNAIDS, requested by UNAIDS Country Office and Tanzania 
Commission for AIDS. 
http://www.tacaids.go.tz/documents/Tanzania%20Epidemiological%20Review%20R
eport.pdf [23.08.2015] 
UNAIDS (2010): Global Report: UNAIDS Report on the Global AIDS Epidemic: 2010. 
UNAIDS, Geneva 2010. http://www.unaids.org/globalreport/Global_report.htm 
[23.08.2015] 
UNAIDS (2013): Global Report: UNAIDS Report on the Global AIDS Epidemic 2013. 
UNAIDS, Geneva 2013. 
http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Global_Report_2013
_en_1.pdf [23.08.2015] 




Ware NC, Idoko J, Kaaya S, Biraro IA, Wyatt MA, Agbaji O, Chalamilla G, Bangsberg DR 
(2009a): Explaining Adherence Success in Sub-Saharan Africa: An Ethnographic 
Study. PLoS Med 6, e1000011 
Ware NC, Idoko J, Kaaya S, Biraro IA, Wyatt MA, Agbaji O, Chalamilla G, Bangsberg DR 
(2009b): Explaining adherence success in sub-Saharan Africa: an ethnographic study. 
PLoS Med 6, e11 
Watt MH, Maman S, Earp JA, Eng E, Setel PW, Golin CE, Jacobson M (2009): „It’s all the 
time in my mind“: facilitators of adherence to antiretroviral therapy in a Tanzanian 
setting. Soc Sci Med 68, 1793-1800 
Watt MH, Maman S, Golin CE, Earp JA, Eng E, Bangdiwala SI, Jacobson M (2010): Factors 
associated with self-reported adherence to antiretroviral therapy in a Tanzanian 
setting. AIDS Care 22, 381-389 
WHO (2002): Coverage of selected health services for HIV/AIDS prevention and care in less 
developed countries in 2001. WHO, Geneva 2002. 
www.who.int/hiv/pub/prev_care/isbn9241590319.pdf [23.08.2015] 




WHO (2003b): Gender Dimensions of HIV Status Disclosure to Sexual Partners: Rates, 
Barriers and Outcomes. A Review Paper. Department of Gender and Women’s 
Health, Family and Community Health (FCH), World Health Organization. Prepared 
by Suzanne Maman and Amy Medley. WHO, Geneva 2003. 
whqlibdoc.who.int/publications/2004/9241590734.pdf [23.08.2015] 
WHO (2006): From access to adherence: the challenges of antiretroviral treatment. 
University of Amsterdam, World Health Organization, Royal Tropical Institute. 
Prepared by Anita Hardon, Sheila Davey, Trudie Gerrits, Catherine Hodgkin, Henry 
Irunde, Joye Kgatlwane, John Kinsman, Alice Nakiyemba and Richard Laing. WHO, 
Geneva 2006. http://apps.who.int/medicinedocs/pdf/s13400e/s13400e.pdf 
[23.08.2015] 
WHO (2008): Towards universal access: scaling up priority HIV/AIDS interventions in the 
health sector: progress report: 2008. World Health Organization, UNAIDS, UNICEF. 
WHO, Geneva 2008. http://www.who.int/hiv/pub/2008progressreport/en/index.html 
[23.08.2015] 
WHO (2010): Transaction prices for Antiretroviral Medicines and HIV Diagnosticsfrom 
2008 to March 2010. A summary report from the Global Price Reporting Mechanism: 
May 2010. WHO, Geneva 2010. 
http://www.who.int/hiv/pub/amds/gprm_report_may10/en/index.html [26.01.2015] 
 
8. Link to the Publication 
36 
 
8. Link to the Publication 
 
Bohle LF, Dilger H, Groß U (2014) HIV-serostatus disclosure in the context of free 
antiretroviral therapy and socioeconomic dependency: Experiences among women living with 







I would like to deeply thank Prof. Dr. Hansjörg Dilger from Freie Universität Berlin and Prof. 
Dr. Uwe Groß from Göttingen University, who accepted me as their doctoral candidate and 
who greatly supported, inspired and motivated me throughout my “doctoral journey”. My 
special thanks goes to Prof. Dilger for accepting me as his (medical) doctoral student and for 
sharing his great knowledge, providing endless support, for his reliability and helpful critical 
thoughts in the field of medical anthropology and beyond.  
I am deeply indepted to every single woman of the CTC, who agreed to be interviewed and 
who were the core of this study.  
For the financial realization of the research project I would like to thank the Gö4med 
scholarship of the Medical Faculty of Goettingen University and the Deutscher Akademischer 
Austauschdienst (DAAD). 
My thanks goes to the Ethical Committee of the Medical Faculty of Goettingen University 
and the National Institute for Medical Research (NIMR) for ethical approval, as well as the 
Commission for Science and Technology (COSTECH) for granting research permission.  
I want to express my deep gratitude to the whole team of the Deutsche Gesellschaft für 
Technische Zusammenarbeit (GTZ, now German International Cooperation (GIZ)) in Dar es 
Salaam, in particular the AIDS Office and Tanzanian-German Programme to Support Health 
(TGPSH) for their generous technical support by granting me the needed facilities in Tanga 
city. Without their help, the realization of the research study would not have been possible. 
Especially I woul like to thank Dr. Bergis Schmidt-Ehry, Dr. Angelika Schrettenbrunner, 
Cornelia Becker, Dr. Balthazar Ngoli, Dr. Yunus Koshuma and Dr. Rainer Külker.  
I am thankful to Dr. Pascal Kanyinyi, at the time Regional Medical Officer of Tanga Region 
and local partner of the study. Thank you to Mr. Selemani Msangi from National AIDS 
Control Programme (NACP) and Simon Collery, who always lended a helping hand and who 
I tortured with questions on data concerning HIV and AIDS in Tanzania – and still do. My 
thanks goes to Dr. Ferdinand Mtatifikolo, at the time director of Bombo Regional Hospital 
and Dr. Margret Mhando for allowing me to conduct the study at the hospital site. I am 
thankful to the whole staff of the CTC of Bombo Regional Hospital – in particular the 
medical doctors who helped in the recruitment of interviewees, as well as the clerk staff, the 
pharmacists, the nurses and the VCTC team.  
Furthermore I would like to thank Dr. Peter Mangesho for his help in finding a research 
assistant. I am deeply thankful to Lilian Mbwambo and Grace Mwakipesile Preuss, my 
interviewers, for their fantastic work done during the study, as well as Alex Mkwizu and 
Acknowledgement 
 
Beatrice Siteyian for translation of the interviews. Besides I want to thank Dr. Peter Memiah 
and Daniel Ole Mtalami for giving me insight into the work of AIDSRelief and helping me 
with further access to literature, as well as Dominik Mattes for his help. 
Furthermore, I would like to thank Dr. Peter Hellmold, Dr. Joseph Mberesero and Anna 
Bezold for sharing their clinical knowledge with me at Bombo Regional Hospital between 
2002 and 2008 and inspiring me.  
I would like to thank Dr. Alexandra Müller and Katharina Dittmer, who helped in 
guaranteeing inter-coder reliability for the analysis of interviews conducted and Frank Albert 
for further translation. For statistical support I want to thank Dr. Jakob Siemerkus and Dr. 
Andreas Cordes. Lisa Mackenrodt I want to thank for her professional help in the 
interpretation of Swahili terms. To Dr. Julia Wangari Muchunu, Dr. Joseph Mberesero, Luiza 
Zena Robi, Lilian Mbwambo, and Grace Mwakipesile Preuss – thank you for sharing your 
knowledge regarding Tanzania and Tanga. For a thorough proofreading of this thesis I want 
to thank Heather Midgordon and Renate Laut from Göttingen University. 
I would like to thank the Freundes- and Förderkreis of the Medical School of Goettingen 
University, which granted me a scholarship for a clinical elective at the Groote Schuur 
Hospital in Cape Town, South Africa in 2006. The experiences gained highly influenced me 
in the development of the questions investigated throughout this research project.  
 
Last but not least my special thanks goes explicitly to everyone not listed above but who 
supported me in person and in the research project in general. 
 
 
 
